4.5 Article

Food supplementation with rice bran enzymatic extract prevents vascular apoptosis and atherogenesis in ApoE-/- mice

Journal

EUROPEAN JOURNAL OF NUTRITION
Volume 56, Issue 1, Pages 225-236

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00394-015-1074-z

Keywords

ApoE-/-; Rice bran enzymatic extract; Atherosclerosis; Inflammation; Apoptosis; Telomeres

Funding

  1. Corona foundation via Stifterverband fur die Deutsche Wissenschaft
  2. Spanish Government
  3. FPU fellowship from Spanish Government

Ask authors/readers for more resources

Atherosclerosis is associated with reduced mononuclear cell (MNC) telomere length, and senescent cells have been detected in atherosclerotic plaques. Rice bran is a source of gamma-oryzanol, phytosterols and tocols with potential lipid-lowering, antioxidant and anti-inflammatory activities. Here, we tested the hypothesis that rice bran enzymatic extract (RBEE) impacts on apoptosis, telomere length and atherogenesis in mice. Seven-week-old male ApoE-/- mice were fed high-fat diet (HFD) or isocaloric HFD supplemented with 5 % (w/w) RBEE for 23 weeks. Wild-type mice of the same age were kept under standard diet as controls. RBEE treatment reduced total cholesterol (19.24 +/- 1.63 vs 24.49 +/- 1.71 mmol/L) and triglycerides (1.13 +/- 0.18 vs 1.75 +/- 0.22 mmol/L) and augmented HDL-cholesterol (1.86 +/- 0.20 vs 1.07 +/- 0.20 mmol/L). RBEE attenuated macrophage infiltration by 56.69 +/- 4.65 % and plaque development (7737 +/- 836 vs 12,040 +/- 1001 mu m(2)) in the aortic sinus. In the aorta, RBEE treatment reduced expression of the apoptosis pathway components p16, p53 and bax/bcl-2 ratio. RBEE prevented apoptosis of aortic endothelial cells (2.81 +/- 0.71-1.14 +/- 0.35 apoptotic nuclei/ring for ApoE-/- HFD and ApoE-/- HFD 5 % RBEE, respectively). In contrast, MNC of RBEE-fed mice exhibited enhanced apoptosis marker expression with increased p53 and bax/bcl-2 protein levels. Compared to WT, ApoE-/- mice on HFD were characterized by significant telomere shortening in aorta (11 +/- 2 %) and MNC (73 +/- 7 %), which was reduced by supplementation with RBEE (aorta: 40 +/- 7 %; MNC: 105 +/- 10 %). Expression of telomere repeat-binding factor 2 was increased in RBEE-fed mice. Long-term food supplementation with RBEE lowers cholesterol and prevents atherosclerotic plaque development in ApoE-/- mice. Differential regulation of vascular and MNC apoptosis and senescence were identified as potential mechanisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy

Daniel Lavall, Nicola H. Vosshage, Romy Gessner, Stephan Stoebe, Sebastian Ebel, Timm Denecke, Andreas Hagendorff, Ulrich Laufs

Summary: Native T1 mapping in patients with left ventricular hypertrophy has high diagnostic accuracy for detecting cardiac amyloidosis.

CLINICAL RESEARCH IN CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses

Paulina E. Stuerzebecher, Jessica J. Schorr, Sven H. G. Klebs, Ulrich Laufs

Summary: This study aimed to characterize patients undergoing Lp(a) testing and evaluate the impact of Lp(a) testing on treatment changes and subsequent ASCVD events. The study found that Lp(a) testing is rarely performed even in patients with high cardiovascular risk. Patients tested for Lp(a) have more comorbidities and a higher ASCVD risk. Lp(a) testing is associated with more intensive preventive treatment and positive effects on clinical outcomes and survival.

ATHEROSCLEROSIS (2023)

Editorial Material Cardiac & Cardiovascular Systems

What is 'remnant cholesterol'?

Paulina E. Stuerzebecher, Julius L. Katzmann, Ulrich Laufs

EUROPEAN HEART JOURNAL (2023)

Letter Hematology

The dose-response of direct oral anticoagulants is non-linear at plasma levels below 100 ng/ml

Michael Metze, Annelie Siegemund, Thomas Siegemund, Tristan Kloeter, Stephan Stoebe, Ulrich Laufs, Sirak Petros, Christian Pfrepper

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

Letter Immunology

Reply to: Apolipoprotein C3 induces inflammasome activation only in its delipidated form

Stephen Zewinger, Jochen Reiser, Vera Jankowski, Dalia Alansary, Eunsil Hahm, Sarah Triem, Mira Klug, Stefan J. Schunk, David Schmit, Rafael Kramann, Christina Koerbel, Emmanuel Ampofo, Matthias W. Laschke, Simina-Ramona Selejan, Anna Paschen, Tobias Herter, Susanne Gaul, Guenther Silbernagel, Martina Sester, Urban Sester, Gunter Assmann, Robert Bals, Gerhard Kostner, Willi Jahnen-Dechent, Michael D. Menger, Lucia Rohrer, Winfried Maerz, Michael Boehm, Joachim Jankowski, Manfred Kopf, Eicke Latz, Barbara A. Niemeyer, Danilo Fliser, Ulrich Laufs, Thimoteus Speer

NATURE IMMUNOLOGY (2023)

Article Medicine, General & Internal

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

S. E. E. Nissen, A. M. Lincoff, D. Brennan, K. K. K. Ray, D. Mason, J. J. P. Kastelein, P. D. D. Thompson, P. Libby, L. Cho, J. Plutzky, H. E. E. Bays, P. M. M. Moriarty, V Menon, D. E. E. Grobbee, M. J. J. Louie, C-F Chen, N. Li, L. A. Bloedon, P. Robinson, M. Horner, W. J. J. Sasiela, J. McCluskey, D. Davey, P. Fajardo-Campos, P. Petrovic, J. Fedacko, W. Zmuda, Y. Lukyanov, S. J. J. Nicholls

Summary: This study demonstrates that the ATP citrate lyase inhibitor Bempedoic acid can significantly reduce low-density lipoprotein cholesterol levels and is associated with a low incidence of muscle-related adverse events. Among patients unable or unwilling to take statins, Bempedoic acid treatment significantly reduces the risk of major adverse cardiovascular events.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Review Cardiac & Cardiovascular Systems

Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)

Maciej Banach, Peter E. Penson, Michel Farnier, Zlatko Fras, Gustavs Latkovskis, Ulrich Laufs, Francesco Paneni, Paolo Parini, Matteo Pirro, Zeljko Reiner, Michal Vrablik, Carlos Escobar

Summary: Cardiovascular disease (CVD) is a chronic non-communicable disease and the leading cause of disability and mortality worldwide. The current lipid-lowering treatments need improvement, and bempedoic acid, as a new approach to reduce lipid levels, has the potential to lower the risk of CVD.

PROGRESS IN CARDIOVASCULAR DISEASES (2023)

Review Cardiac & Cardiovascular Systems

Pathophysiological Gaps, Diagnostic Challenges, and Uncertainties in Cardiac Sarcoidosis

Laura Ueberham, Andreas Hagendorff, Karin Klingel, Ingo Paetsch, Cosima Jahnke, Theresa Kluge, Hans Ebbinghaus, Gerhard Hindricks, Ulrich Laufs, Borislav Dinov

Summary: Cardiac sarcoidosis can mimic any cardiomyopathy due to nonhomogeneous distribution of inflammation in the heart. The current diagnostic criteria are inconsistent and partly nonspecific and insensitive. In addition to the diagnostic challenges, there are controversies surrounding the causes, genetic and environmental background, and natural evolution of the disease. This review highlights the current understanding and research gaps in the pathophysiology of cardiac sarcoidosis that will be relevant for future diagnostics and research.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Article Health Care Sciences & Services

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

Kausik K. Ray, Inaam Haq, Aikaterini Bilitou, Marius C. Manu, Annie Burden, Carlos Aguiar, Marcello Arca, Derek L. Connolly, Mats Eriksson, Jean Ferrieres, Ulrich Laufs, Jose M. Mostaza, David Nanchen, Ernst Rietzschel, Timo Strandberg, Hermann Toplak, Frank L. J. Visseren, Alberico L. Catapano

Summary: The SANTORINI study found that in Europe between 2020 and 2021, statin monotherapy was the main approach to lipid management for high-risk and very high-risk cardiovascular patients, with only one-fifth achieving the recommended LDL-C goals. The study results raised questions about whether there have been changes in the treatment landscape or if gaps still exist.

LANCET REGIONAL HEALTH-EUROPE (2023)

Article Clinical Neurology

Extent of routine diagnostic cardiac work-up at certified German stroke units participating in the prospective MonDAFIS study

Manuel C. Olma, Serdar Tuetuencue, Ulrike Grittner, Claudia Kunze, Muhammad Jawad-Ul-Qamar, Paulus Kirchhof, Joachim Roether, Goetz Thomalla, Roland Veltkamp, Ulrich Laufs, Darius G. Nabavi, Peter U. Heuschmann, Matthias Endres, Karl Georg Haeusler

Summary: Little is known about the extent and standardization of routine cardiac diagnostic work-up at certified stroke-units in Germany. This study analyzed the routine diagnostic work-up at different stroke centres in Germany and found that detection of atrial fibrillation (AF) varied among the centres, with lower detection rates in university-based comprehensive stroke centres compared to non-university-based and primary stroke centres. The use of echocardiography and Holter-ECG monitoring also differed among the centres.

NEUROLOGICAL RESEARCH AND PRACTICE (2023)

Article Cardiac & Cardiovascular Systems

Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2 study-rationale and design

Tobias Uhe, Katrin Wasser, Mark Weber-Krueger, Wolf-Ruediger Schaebitz, Martin Koehrmann, Johannes Brachmann, Ulrich Laufs, Martin Dichgans, Goetz Gelbrich, David Petroff, Christiane Prettin, Dominik Michalski, Andrea Kraft, Thorleif Etgen, Peter D. Schellinger, Hassan Soda, Florian Bethke, Michael Ertl, Bernd Kallmuenzer, Martin Grond, Katharina Althaus, Gerhard F. Hamann, Meinhard Mende, Marcus Wagner, Sonja Groeschel, Timo Uphaus, Klaus Groeschel, Rolf Wachter

Summary: This study aims to evaluate whether risk-adapted, intensified heart rhythm monitoring with consequent guideline conform treatment can reduce the recurrence of cardioembolism. The study will include patients aged 60 and above who have had a symptomatic ischemic stroke within the last 30 days. They will be randomly assigned to either an intervention group or a control group.

AMERICAN HEART JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

U. Makhmudova, U. Schatz, N. Perakakis, U. Kassner, F. Schumann, C. Axthelm, P. Stuerzebecher, D. L. Sinning, A. Doevelaar, B. Rohn, T. Westhoff, A. Vogt, M. Scholl, U. Kaestner, J. -A. Geiling, K. Stach, J. Mensch, E. Lorenz, C. Paitazoglou, I. Eitel, A. Baessler, E. Steinhagen-Thiessen, W. Koenig, P. C. Schulze, U. Landmesser, U. Laufs, Oliver Weingaertner, German Inclisiran Network GIN

Summary: Inclisiran, a new drug that targets PCSK9 mRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia. In a German study, inclisiran demonstrated a median LDL-C reduction of 35.5% at 3 months and 26.5% at 9 months. Patients previously treated with PCSK9 antibodies showed lower LDL-C reductions compared to statin-treated patients at the 3-month mark.

CLINICAL RESEARCH IN CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Physical exercise as a treatment for persisting symptoms post-COVID infection: review of ongoing studies and prospective randomized controlled training study

Alexander Kogel, Moritz Machatschek, Ronja Scharschmidt, Carolin Wollny, Florian Lordick, Mohamed Ghanem, Ulrich Laufs, Sven Fikenzer

Summary: This study found that physical exercise after COVID-19 infection can safely and effectively improve maximal exercise capacity and quality of life in patients. Fatigue decreases over time. Additionally, individuals who participated in the exercise program had significantly higher levels of physical activity during the follow-up period compared to those in the control group.

CLINICAL RESEARCH IN CARDIOLOGY (2023)

Review Medicine, General & Internal

Lipid Profile and Lipoprotein(a) Testing

Klaus G. Parhofer, Ulrich Laufs

Summary: The treatment of dyslipidemias is crucial for the prevention of cardiovascular disease. Evaluation of lipid status and monitoring of treatment effects can guide therapy. The main goal is to lower LDL-cholesterol through lifestyle changes and medication.

DEUTSCHES ARZTEBLATT INTERNATIONAL (2023)

Article Cardiac & Cardiovascular Systems

The impact of upright posture on left ventricular deformation in athletes

J. Kandels, M. Metze, A. Hagendorff, R. P. Marshall, P. Hepp, U. Laufs, S. Stoebe

Summary: In addition to LV ejection fraction (LVEF), global longitudinal strain (GLS) and global myocardial work index (GWI) are crucial for evaluating left ventricular (LV) function in athletes. This study investigated the effects of upright posture on GLS and GWI during echocardiography. The results showed that GLS and GWI were lower in upright posture, particularly in the mid-basal inferior and/or posterolateral segments. These findings highlight the importance of considering the impact of upright posture in athletes' echocardiographic assessments.

INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2023)

No Data Available